Therapeutic area intelligence for Chronic Hepatitis B with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Ausper Biopharma →

Assets

AHB-171 →

Recent signals(2)

ClinicalJuly 28, 2026

Study on Timing of Withdrawal from Long-Term Antiviral Treatment for Chronic Hepatitis B

A study is underway to evaluate the safety and effectiveness of withdrawing antiviral treatment after 4 years in chronic hepatitis B patients.

ClinicalJuly 18, 2026

Ausper Biopharma initiates AHB-171 trial for chronic hepatitis B

Ausper Biopharma is conducting an open-label trial to assess the efficacy and safety of AHB-171 in chronic hepatitis B patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Chronic Hepatitis B →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.